Pharmacoeconomic review report: Latanoprostene bunod (Vyzulta) : (Bausch Health Canada Inc.)

Latanoprostene bunod (LBN) 0.024% ophthalmic solution (Vyzulta) is indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). It is available as a sterile topical ophthalmic solution containing 0.24 mg/mL LBN supplied in an eye-...

Full description

Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health August 2019, 2019
Edition:Version: final
Series:CADTH common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:Latanoprostene bunod (LBN) 0.024% ophthalmic solution (Vyzulta) is indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). It is available as a sterile topical ophthalmic solution containing 0.24 mg/mL LBN supplied in an eye-drop dispenser with a 5 mL fill volume. The recommended dosage is one drop in the affected eye(s) once daily. At the manufacturer-submitted price of $26.25 per dispenser, LBN costs approximately $0.30 per day, assuming treatment of both eyes. The manufacturer submitted a cost-utility analysis comparing LBN with currently available prostaglandin analogues (PGAs) for the treatment of patients with OHT and OAG (bimatoprost 0.01%, bimatoprost 0.03%, generic latanoprost 0.005%, and travoprost 0.004%). All patients were assumed to have both eyes treated
Physical Description:1 PDF file (33 pages) illustrations